Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

October 12, 2026
9 min

The Medicine Maker

Overview

Amy Jensen-Smith describes her transition from laboratory research to scientific leadership and her current role overseeing SOTIO Biotech’s preclinical antibody-drug conjugate (ADC) pipeline for solid tumors. She emphasizes identifying a program’s most critical uncertainty early, testing it first, and moving on quickly if the approach does not hold up.

Background

ADCs combine an antibody that recognizes a tumor with potent chemotherapy, with the aim of delivering the chemotherapy to the tumor. Jensen-Smith’s work at SOTIO spans target and technology generation through preclinical development and preparation for clinical testing. She says drug candidates must align target biology and disease context with the needs of the intended patient population and practical feasibility. Her career has included academia, the National Cancer Institute, Novartis, bluebird bio, and SOTIO Biotech.

Data Highlights

The interview reports no numerical trial or clinical outcome data. It describes SOTIO’s focus on ADC development for solid tumors and Jensen-Smith’s oversight of the preclinical pipeline.

Key Findings

As SOTIO’s Chief Scientific Officer, Jensen-Smith oversees preclinical research from new target or technology ideas through preparation for clinical development.
She says strategic decisions consider unmet medical need, the capabilities of the technology, potential applications, and the company’s ability to sustain drug development.
She describes moving from bench science to leadership as requiring trust in others to generate and interpret experimental data, while allowing scientific questions to be considered more broadly.
Her approach to novel targets is to identify the program’s “Achilles’ heel” and run the most critical experiment at the outset rather than proceeding sequentially.
She characterizes early testing as a way to fail fast and move to another idea when a program does not withstand its key test.
She says drug-candidate development requires connecting target biology and disease context with the intended patient population and practical feasibility.

Clinical Implications

The interview presents early testing of a program’s most critical assumption as SOTIO’s approach to preclinical ADC research; it does not report clinical evidence evaluating this strategy. Jensen-Smith also describes unmet medical need, technology capabilities, disease biology, patient population, and feasibility as considerations in selecting and advancing programs.

Conclusion

Jensen-Smith’s account links scientific leadership with a focused approach to preclinical drug development: identify the central uncertainty, test it early, and advance programs that withstand that test. The interview provides career and organizational perspectives rather than clinical trial findings.